Defective Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses in an Immunocompromised Individual With Prolonged Viral Replication

Article Immunology

Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?

Chanu Rhee et al.

Summary: SARS-CoV-2 is most contagious around symptom onset, with infectivity rapidly decreasing to near-zero afterwards; mild-moderately ill patients can safely discontinue isolation after about 10 days, while severely-critically ill and immunocompromised patients may need 15 days. The longest duration associated with replication-competent virus is 20 days.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

Ji Hoon Baang et al.

Summary: This case illustrates challenges in managing immunocompromised hosts with chronic COVID-19, who may act as persistent shedders and sources of transmission. The patient's lack of seroconversion and prolonged course highlight the importance of humoral immunity in resolving viral infections.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy-A Prospective Longitudinal Study

Ana Copaescu et al.

Summary: The study found that IL-6 levels were elevated in hospitalized SARS-CoV-2 positive patients on admission, but were lower compared to matched SAB patients. IL-6 and CRP levels decreased post-treatment, with a more significant reduction in patients treated with remdesivir and/or dexamethasone. CRP and bedside vital signs were the strongest predictors of COVID-19 severity.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study

Chiara Sepulcri et al.

Summary: Immunocompromised patients can have prolonged shedding of SARS-CoV-2 and clinical relapses of COVID-19, with differences in cell immune dynamics and absence of virus-specific antibodies detected.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Article Biochemistry & Molecular Biology